Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 7;21(1):676.
doi: 10.1186/s12885-021-08418-y.

Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

J Ripoll  1   2 , M Ramos  3   4 , J Montaño  2   5 , J Pons  6 , A Ameijide  7 , P Franch  2   6
Affiliations

Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

J Ripoll et al. BMC Cancer. .

Erratum in

Abstract

Background: Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.

Methods: Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry.

Inclusion criteria: cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis.

Results: One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65 years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5 years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival.

Conclusion: Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival.

Keywords: Bladder neoplasms; Multiple imputation; Stage; Survival.

PubMed Disclaimer

Conflict of interest statement

We declare that we have no competing interests.

Figures

Fig. 1
Fig. 1
Survival of bladder cancer cases diagnosed in Mallorca between 2006 and 2011 by sex, age, diagnostic method and histology
Fig. 2
Fig. 2
Survival by stage of bladder cancer cases diagnosed in Mallorca between 2006 and 2011 after multiple imputation
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Galceran J, Carulla M, Almela F, Chico M, Marcos AI, Marcos-Gragera R, et al. Oral communication presented at: XLIV Annual Meeting of the Groupe pour l’Epidémiologie et l’Enregistrement du Cancer dans les Pays de Langue Latine; 2019, 29–31 May. Lisbon; 2019.
    1. Mortalidad de cáncer en España. Instituto de Salud Carlos III. Available at: http://ariadna.cne.isciii.es/MapaP/ [checked the 08 Sept 2019].
    1. Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, Sant M, and the EUROCARE-5 Working Group Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217–2230. doi: 10.1016/j.ejca.2015.07.028. - DOI - PubMed
    1. Kamat AM, Hahn NM, Efstathiou JA, Lerner SSP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016;388(10061):2796–2810. doi: 10.1016/S0140-6736(16)30512-8. - DOI - PubMed

MeSH terms